Undoubtedly, the best chapter in the volume is James Robinson's discussion of why PGPs have not thrived. As Robinson says, for a variety of perhaps good reasons, government has not developed a supportive tax and regulatory framework; purchasers have not moved to offer multiple plans with a fixed-dollar payment; health plans have not built integrated networks; and physician groups have not assumed more financial risk or developed new organizational forms.
In the book's final chapters, Alain Enthoven proposes reforms for the 21 st century. These have a familiar ring: consumer choice of health plans, perhaps with insurance exchanges like the Federal Employees Health Benefit plan or CalPERS; level-dollar premium contributions by employers; objective consumer information on quality and price; and the subsidization of new PGPs. All these reforms are developed in the context of limited tax deductibility of employer-sponsored health insurance. However, in light of the reports in this volume, the recent research on employersponsored health insurance relating to premium contributions, and the limited effectiveness to date of the role of quality information in consumer choices, perhaps a less encompassing reform is in order. Let's begin simply with Enthoven's long-standing proposal for a refundable tax credit in place of the existing tax treatment of health insurance. Coping with Methuselah is a compendium of seven chapters in which 11 authors (plus commentators) explore, first, whether molecular medicine will significantly accelerate increases in longevity (the answer is ''yes'') and, second, the implications of greater proportions of people, particularly in developed countries, being ''Methuselah'' populations. This is not a Malthusian tome; it constructs no doomsday scenarios. Rather, it is a careful, academic overview of a number of related issues surrounding people living significantly longer. The consensus among the authors is that even if natural limits exist for human life expectancy, we have not yet reached them, and we will increasingly extend life span in the coming century. Public policy, at least for developed countries, should encourage splitting added years of life between productivity and leisure (by raising, for example, the age of eligibility for health and retirement benefits by one month per year). This could minimize or even eliminate future fiscal trauma associated with living longer. Fiscally, at least, we can cope with Methuselah, though that is conditional on the political will to act sooner rather than later.
The book is well integrated with chapters cross-referenced to avoid repetitious recitals of basic concepts common to various perspectives. As would be expected in any collection, the chapters are somewhat uneven in style and density of writing. This is not light reading, though the chapters on health care, Social Security/ Medicare/Medicaid, and ethics are especially accessible.
The overall plan of the collection is first to address biomedical research and technology as potential drivers of longevity, then to discuss the demographic and health care implications of increased longevity, and to examine economic implications for labor markets, retirement programs (especially Social Security), and public-sector health programs such as Medicare and Medicaid. The volume concludes with discussions of ethical issues and global perspectives.
In discussing biomedical research and its application, the authors set forth two general cautions: First, it nearly always takes longer than forecast to achieve a sought-after result; second, the long-term effects of those results, if achieved, are nearly always far greater than forecast. Most attention is given to prevention and treatment of known processes that limit life expectancy including cardiovascular, infectious, and neurodegenerative diseases, cancer, and obesity. Regenerative medicine receives brief treatment, and the authors/editors are careful to focus on science and avoid political aspects of stem-cell research and gene therapy.
Given that additional longevity will increasingly accrue, the questions then are: How soon does this happen? How are added years of life divided between productive work and leisure? What is the quality of life/cost of maintaining life in those years?
Several concepts in the arena of health and medical care are strongly reaffirmed: 1) ''moral hazard'' is real; 2) curing/preventing one or more fatal diseases allows more of us to die of another fatal disease with its attendant costs (e.g., taking care of cancer and cardiovascular disease would keep more of us around a bit longer to encounter Alzheimer's); 3) as observers of Medicare have known for the last quarter century, the number of years elapsed since birth (age) tells us little about per capita medical care costs-rather the important variable is the number of years remaining until death (and/or current functional status); 4) reducing the cost of health care tends to confer greater benefits on the rich than on the poor. These reminders are especially important since policymakers so often forget about them.
The ethics chapter provides a basic summary of utilitarian and justice-based models in the context of health care generally and life extension in particular. The chapter concludes by addressing and largely rebutting the arguments of some that it is inappropriate per se to prolong human life.
The global perspective chapter models savings/investment rates in a world of increased longevity for the full spectrum of countries with high, medium, and low incomes. One possible outcome is that rich nations with older populations needing to expand savings rates will complement the need for added capital by the developing world and its younger populations.
In sum, this book is well worth the investment to purchase and absorb.
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